Armstrong A. Diagnosis and management of endometrial hyperplasia. The Journal of Minimally Invasive Gynecology. Costales A, et al.

Author:Kigagrel Faenos
Language:English (Spanish)
Published (Last):11 July 2004
PDF File Size:15.6 Mb
ePub File Size:14.91 Mb
Price:Free* [*Free Regsitration Required]

Clinical Treatment and Follow-up of Endometrial Hyperplasia. Resultados: foram analisadas 42 pacientes com hiperplasia endometrial sem atipia e cinco com atipia. Sangramento uterino anormal. Kurman et al. Ferenczy et al. Gal et al. Purpose: to evaluate the efficacy of medroxyprogesterone acetate and megestrol acetate in endometrial hyperplasia. Patients and Methods: forty-seven patients with abnormal uterine bleeding were retrospectively evaluated.

The length of treatment ranged from 3 to 18 months. Results: forty-two patients with endometrial hyperplasia without atypia and 5 with hyperplasia with atypia were included. The mean age of the patients was Medroxy-progesterone acetate was effective in promoting regression of Despite treatment, lesions persisted in No progression to endometrial cancer was seen during the follow-up period of 3 months to 9 years.

During follow-up, we found that 18 patients Histological examination of the uterus showed 8 patients with persistence of hyperplastic lesion, 4 with leiomyoma, 3 with adenomyosis, 1 with diffuse uterine myohypertrophy, and 1 with normal uterus, despite regression of the hyperplastic lesions in 9 of the 17 patients.

Conclusions: the treatment of endometrial hyperplasia with medroxyprogesterone acetate and megestrol acetate can be a safe alternative for women who refuse to have their uterus removed or those at high risk for surgery. However, a careful monitoring of the endometrium is needed. This can be achieved with periodical endometrial biopsy, transvaginal ultrasonography, and evaluation of the symptoms. Medroxy-progesterone acetate. Endometrium: neoplasms. Uterine bleeding, abnormal.

Endometrial hyperplasia and related cellular changes. In: Kurman RJ, editor. Blaustein's Pathology of the Female Genital Tract. New York: Springer-Verlag; Endometrial hyperplasia. Infert Reprod Med ; Endometrial cancer: Factors influencing the choice of treatment. Gynecol Oncol ; Vellios F. Endometrial hyperplasia and carcinoma in situ. The behavior of endometrial hyperplasia. A long term study of "untreated" hyperplasia in patients. Cancer ; The cytodynamics of endometrial hyperplasia and carcinoma.

A review. Ann Pathol ; Review of the endometrial effects of estrogens and progestins. Obstet Gynecol Surg ; Wentz WB. Treatment of persistent endometrial hyperplasia with progestagen. Am J Obstet Gynecol ; Eichner E, Abellera M. Endometrial hyperplasia treated by progestagens. Obstet Gynecol ; Long-term effect of megestrol acetate in the treatment of endometrial hyperplasia.

Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestogen treated endometrial hyperplasia. Estradiol binding and metabolism in human endometrial hyperplasia and adenocarcinoma. J Steroid Biochem ; Progesterone inhibits the estrogen induced expression of C-fos-messenger ribonucleic acid in the uterus.

Endocrinology ; Effects of progestogens on human endometrium. Obstet Gynecol Surv ; Kopelman PG. Investigation of obesity. Clin Endocrinol ; American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care ; Progestin therapy in endometrial hyperplasia. Precancerous lesions of the endometrium and medical treatment.

Endometrial adenomatous hyperplasia analysis of the karyometric variations caused by medroxyprogesterone acetate. Rev Assoc Med Bras ; Progestin treatment of atypical hyperplasia and well diferenttiated carcinoma of the endometrium in women under age Endometrial hyperplasia and endometrial cancer.

Obstet Gynecol Clin North Am ; The behavior of endometrial hyperplasia a prospective study. Endometrial hyperplasia study group. J Obstet Gynecol Res ; Whitehead MI. Progestins and androgens. Fertil Steril ; 62 Suppl. Services on Demand Journal. All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License.

How to cite this article.


2016, NĂºmero 620




DECRETO 5825 DE 2006 PDF




Related Articles